title: Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced experimental otitis media.
abstract: OBJECTIVE
  The purpose of this study is to compare the effect of topical ciprofloxacin/dexamethasone versus topical ciprofloxacin/hydrocortisone on the outcome of lipopolysaccharide (LPS)–induced otitis media with effusion in chinchillas.
  
  
  METHODS
  A randomized experimental animal study.
  
  
  METHODS
  Jerry L. Pettis Veteran's Medical Center.
  
  
  METHODS
  Otitis media with effusion was induced in 5 groups of chinchillas, 6 per group, by injecting 0.3 mL (1 mg/mL) of Salmonella enteric LPS into the superior bullae of each chinchilla with a venting needle in place. Each group was treated with 0.2 mL of test substance at –2, 24, 48, and 72 hours relative to the 0-hour LPS induction. Group 1 was treated with vehicle control. Groups 2 to 5 received 0.3% ciprofloxacin with either 0.1% dexamethasone (group 2), 1% dexamethasone (group 3), 0.1% hydrocortisone (group 4), or 1% hydrocortisone (group 5). The outcome of each treatment was measured by the amount of middle ear effusion present and mucosal thickness at 120 hours posttreatment.
  
  
  RESULTS
  Ciprofloxacin/dexamethasone 1% significantly (P = .0150) reduced middle ear effusion compared with control. Ciprofloxacin/dexamethasone 1% significantly reduced the mucosal thickness when compared with vehicle control (P = .0005), ciprofloxacin/dexamethasone 0.1% (P = .0240), and ciprofloxacin/hydrocortisone 0.1% (P = 1.00). Results also showed a dose-response effect between the ciprofloxacin/dexamethasone concentrations.
  
  
  CONCLUSIONS
  This study demonstrated that treatment with a combination of topical ciprofloxacin and corticosteroid decreased the middle ear effusion when compared with the control group and that ciprofloxacin/dexamethasone suspension reduced the severity of LPS-induced experimental otitis media more than ciprofloxacin/hydrocortisone did.
authors.affiliation: Division of Otolaryngology–Head & Neck Surgery, Loma Linda University School of Medicine, Loma Linda, California, USA.
authors.forename: Piali
authors.initials: P
authors.lastname: Dattaray
authors.forename: Charles
authors.initials: C
authors.lastname: Pudrith
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Nyc
authors.forename: Dusan
authors.initials: D
authors.lastname: Martin
authors.forename: You Hyun
authors.initials: YH
authors.lastname: Kim
authors.forename: Patrick
authors.initials: P
authors.lastname: Jahng
authors.forename: You Sun
authors.initials: YS
authors.lastname: Chung
authors.forename: G Michael
authors.initials: GM
authors.lastname: Wall
authors.forename: Timothy
authors.initials: T
authors.lastname: Jung
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002682:Chinchilla; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006854:Hydrocortisone / Q000008:administration & dosage*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D010034:Otitis Media with Effusion / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D010521:Periosteum / Q000187:drug effects / Q000473:pathology; D013701:Temporal Bone / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D008070:Lipopolysaccharides; D002939:Ciprofloxacin; D003907:Dexamethasone; D006854:Hydrocortisone